

## THE COMPANY

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS).

The Company is currently focused on urology and critical care products designed to aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and the traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome.

## THE TECHNOLOGY

Urodynamix's first NIRS technology was licensed from the University of British Columbia (UBC) in Vancouver, BC. The Company has conducted extensive clinical trials and demonstrated the safety and efficacy of this non-invasive diagnostic technique for a range of diverse applications in the fields of urology and critical care.


Urodynamix's first product, the Tetra™ Bladder Monitor System for non-invasive urodynamics, is marketed worldwide by Laborie Medical Technologies. Next generation products will provide non-invasive urodynamics capabilities for office-based urologists.

## URO-NIRS HOW DOES IT WORK?

### Near-Infrared Spectroscopy (NIRS)

A sensor emits near-infrared laser light into the body using a self-adhesive patch. Tissue scatters and absorbs some of the light, and some returns to a detector on the sensor patch.

Absorption of the light by hemoglobin and cytochromes reveals changes in the concentrations of these molecules, allowing continuous, non-invasive monitoring of bladder function.



## MARKET POTENTIAL

- The global market for conventional urodynamics equipment and disposables is \$119 million (2006) and is expected to reach \$147 million by the end of 2013.
- Urinary incontinence (UI) affects over 200 million people worldwide (including 30 million in North America alone) and costs \$463 million per year in the US alone.
- Prostate cancer affects over 250,000 new people in North America each year and costs \$10 billion per year in the US alone.
- Intra-abdominal hypertension (elevated IAP) affects up to half of the 5 million adult ICU patients treated in 60,000 ICU beds in the US each year.

## INVESTMENT HIGHLIGHTS

- Portfolio of disruptive NIRS-based medical products targeting large and growing global healthcare markets
- Clinically validated, FDA approved technology and strong intellectual property
- Global distribution agreement with Laborie Medical Technologies, the world leader in diagnostic urology equipment
- Management team with proven track record
- Current clinical applications
  - Urinary incontinence (UI)
  - Intra-abdominal pressure (IAP) monitoring
  - Prostate cancer (PCa) imaging

## CAPITAL STRUCTURE

TSX Venture Listing: URO

Shares Outstanding: 82.0M

Fully Diluted: 89.3M

Market Capitalization: \$18M

## MANAGEMENT TEAM

**Barry Allen** — President & CEO

**Kevin Leong, CA** — Chief Financial Officer

**Luya Li, PhD** — VP, Technology

**Greg Gauthier** — VP, Business Development

**Craig Pamplin, PhD, CFA** — Director, Corporate Development & Communications

**André Kindsvater, PEng** — Director, RA & QA

**Francine Catonio** — Director, Clinical Services

## BOARD OF DIRECTORS

**Barry Allen** — Chairman

**Paul Geyer, PEng** — President & CEO, Medical Ventures Corp.

**David Goodkin, MD, FACP** — VP, Xenon Pharmaceuticals

**Jim Heppell, LLB** — President & Fund Manager, BC Advantage Funds

**Pierre Leduc** — Executive Chairman, Ondine Biopharma

**Zeid Mohamedali, MD, PhD, FRCS** — Consultant Urologist

## MEDICAL ADVISORY BOARD

**Andrew Macnab, MD, FRCP** — University of British Columbia

**Sender Herschorn, MDCM, FRCS** — University of Toronto


**Tom F. Lue, MD** — University of California, San Francisco

**Zeid Mohamedali, MD, PhD, FRCS** — Consultant Urologist

**Sidney Radomski, MD, FRCS** — University of Toronto

**Lynn Stothers, MD, FRCS** — University of British Columbia

NIRS DEVELOPMENT STATUS



URINARY INCONTINENCE (UI)

NIRS Bladder Monitor™ Technology is designed to provide a catheter-free product for integration with existing hospital- and office-based diagnostic equipment that is faster, cheaper, easier to use, and more user-friendly than existing UDS equipment.

Market Need

- The World Health Organization estimated that UI affects over 200 million people worldwide.
- UI affects 20% of people over 40 and 40% of people over 60 with annual financial costs of \$26B in the US.
- 1 in 10 women in the US require surgery to treat UI or related conditions.

INTRA-ABDOMINAL PRESSURE (IAP)

NIRS IAP™ Technology is designed to provide a continuous, non-invasive IAP monitoring technology for integration into patient monitoring equipment to reduce the cost, morbidity and mortality associated IAP and abdominal compartment syndrome.

Market Need

- 5 million adult patients are monitored and treated in 60,000 ICU beds in the US each year.
- Approximately 50% of trauma ICU patients develop elevated intra-abdominal pressure (IAP) and 10% progress to ACS, which is fatal if not promptly diagnosed and treated.
- The direct costs of treating ICU patients is approximately \$55 bil-



Tetra™ Bladder Monitor System by Laborie for non-invasive urodynamics

PROSTATE CANCER

NIRS DRE™ Technology is designed to provide the world's first office based imaging device for the measurement of blood flow in the prostate to aid in the diagnosis and treatment of prostate cancer and disease.

Market Need

- Vast market, with 150 million men in the US, Europe and Japan qualify for annual prostate cancer screening.
- The most commonly diagnosed non-skin cancer in North America with 250,000 new cases and 30,000 deaths per year
- Prostate cancer treatment and biopsies cost \$10 billion per year in the US

CONTACT

**HEAD OFFICE** Urodynamix Technologies Ltd.  
Suite 1351-409 Granville Street  
Vancouver, British Columbia  
Canada V6C 1T2  
  
Telephone: 604.694.7770  
Fax: 604.694.7771  
Email: info@urodynamix.com

INVESTOR RELATIONS

Craig Pamplin, PhD, CFA  
Director, Corporate Development  
and Communications  
  
Phone: 604.638.0247  
Fax: 604.694.7771  
Email: cpamplin@urodynamix.com